000086405 001__ 86405
000086405 005__ 20210310171108.0
000086405 0247_ $$2doi$$a10.1177/1756284819847034
000086405 0248_ $$2sideral$$a115097
000086405 037__ $$aART-2019-115097
000086405 041__ $$aeng
000086405 100__ $$aChaparro, M.
000086405 245__ $$aEpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
000086405 260__ $$c2019
000086405 5060_ $$aAccess copy available to the general public$$fUnrestricted
000086405 5203_ $$aBackground: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes. Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded. Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up. Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.
000086405 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI16-01296$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-00143
000086405 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000086405 590__ $$a3.52$$b2019
000086405 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b40 / 88 = 0.455$$c2019$$dQ2$$eT2
000086405 592__ $$a1.29$$b2019
000086405 593__ $$aGastroenterology$$c2019$$dQ1
000086405 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000086405 700__ $$aBarreiro-de Acosta, M.
000086405 700__ $$aBenítez, J.M.
000086405 700__ $$aCabriada, J.L.
000086405 700__ $$aCasanova, M.J.
000086405 700__ $$aCeballos, D.
000086405 700__ $$aEsteve, M.
000086405 700__ $$aFernández, H.
000086405 700__ $$aGinard, D.
000086405 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón, F.$$uUniversidad de Zaragoza
000086405 700__ $$aLorente, R.
000086405 700__ $$aNos, P.
000086405 700__ $$aRiestra, S.
000086405 700__ $$aRivero, M.
000086405 700__ $$aRobledo, P.
000086405 700__ $$aRodríguez, C.
000086405 700__ $$aSicilia, B.
000086405 700__ $$aTorrella, E.
000086405 700__ $$aGarre, A.
000086405 700__ $$aGarcía-Esquinas, E.
000086405 700__ $$aRodríguez-Artalejo, F.
000086405 700__ $$aGisbert, J.P.
000086405 700__ $$aAlfambra, E.
000086405 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000086405 773__ $$g12 (2019), 1-11$$pTherap. adv. in gastroenterol.$$tTherapeutic Advances in Gastroenterology$$x1753-283X
000086405 8564_ $$s2088779$$uhttps://zaguan.unizar.es/record/86405/files/texto_completo.pdf$$yVersión publicada
000086405 8564_ $$s122939$$uhttps://zaguan.unizar.es/record/86405/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000086405 909CO $$ooai:zaguan.unizar.es:86405$$particulos$$pdriver
000086405 951__ $$a2021-03-10-17:01:26
000086405 980__ $$aARTICLE